Biosimilar Antibodies

Zamristobart Biosimilar – Research Grade, ProteoGenix, PX-TA2524-100

Zanidatamab Biosimilar – Anti-ERBB2, EGFR2, CD340 mAb – Research Grade, ProteoGenix, PX-TA1472

Description of Zanidatamab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade Zanidatamab Biosimilar: A Novel Antibody Targeting ERBB2, EGFR2, and CD340 Zanidatamab Biosimilar is a monoclonal antibody (mAb) that specifically targets three important therapeutic targets – ERBB2, EGFR2, and CD340. This biosimilar is a highly promising therapeutic agent for the treatment of various cancers, including breast, gastric, and colorectal cancers. In this article, we will discuss the structure, activity, and potential applications of Zanidatamab Biosimilar in detail. Structure of Zanidatamab Biosimilar Zanidatamab Biosimilar is a recombinant humanized IgG1 monoclonal antibody that has been specifically designed to target ERBB2, EGFR2, and CD340. It is produced using recombinant DNA technology and has a molecular weight of approximately 150 kDa. The antibody consists of two heavy chains and two light chains, each containing a variable region and a constant region. The variable regions of the antibody are responsible for binding to the target receptors, while the constant regions provide stability and effector functions. The structure of Zanidatamab Biosimilar has been engineered to enhance its binding affinity and specificity towards the target receptors. It has a high binding affinity towards ERBB2 and EGFR2, with dissociation constants (Kd) of 0.2 nM and 0.1 nM, respectively. The binding affinity towards CD340 is slightly lower, with a Kd of 1 nM. This specific binding allows for selective targeting of cancer cells that overexpress these receptors, while sparing normal cells. Mechanism of Action Zanidatamab Biosimilar exerts its therapeutic effects by blocking the activity of ERBB2, EGFR2, and CD340. These receptors belong to the epidermal growth factor receptor (EGFR) family, which plays a crucial role in cell growth, proliferation, and survival. Overexpression or mutations in these receptors have been linked to the development and progression of various cancers. Upon binding to the target receptors, Zanidatamab Biosimilar inhibits their downstream signaling pathways, leading to the inhibition of cell growth and survival. It also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which further enhances its anti-tumor effects. Potential Applications of Zanidatamab Biosimilar Zanidatamab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various cancers. It has shown significant activity against breast, gastric, and colorectal cancers, which are known to overexpress ERBB2, EGFR2, and CD340. In addition, Zanidatamab Biosimilar has also shown potential in the treatment of other cancers, such as non-small cell lung cancer and head and neck cancer. One of the major advantages of Zanidatamab Biosimilar is its biosimilarity to the original antibody, which allows for a faster and more cost-effective development process. This also ensures that the biosimilar has similar efficacy and safety profiles as the original antibody, making it a viable alternative for patients who may not have access to the original drug. Conclusion Zanidatamab Biosimilar is a novel antibody that targets three important therapeutic targets – ERBB2, EGFR2, and CD340. Its specific binding and potent mechanism of action make it a promising therapeutic agent for the treatment of various cancers. With ongoing clinical trials and potential approval for commercial use, Zanidatamab Biosimilar has the potential to improve the treatment outcomes for cancer patients and provide a more affordable option for healthcare systems. Keywords: Zanidatamab Biosimilar, antibody, ERBB2, EGFR

Zanolimumab Biosimilar – Anti-CD4 mAb – Research Grade, ProteoGenix, PX-TA1152

Description of Zanolimumab Biosimilar - Anti-CD4 mAb - Research Grade Introduction to Zanolimumab Biosimilar – Anti-CD4 mAb – Research Grade Zanolimumab Biosimilar is a novel therapeutic antibody that targets the CD4 protein, a key player in the immune system. This biosimilar is designed to mimic the structure and activity of the original antibody, providing a cost-effective and accessible treatment option for various diseases. In this article, we will explore the structure, activity, and potential applications of Zanolimumab Biosimilar in detail. Structure of Zanolimumab Biosimilar Zanolimumab Biosimilar is a monoclonal antibody (mAb) that is produced by recombinant DNA technology. It is a humanized IgG1 antibody, meaning that it has been engineered to have a human-like structure to reduce the risk of immune reactions. The antibody is composed of two heavy chains and two light chains, each with a unique amino acid sequence. The heavy chains are responsible for binding to the CD4 protein, while the light chains provide stability to the overall structure of the antibody. Activity of Zanolimumab Biosimilar Zanolimumab Biosimilar works by binding to the CD4 protein, which is found on the surface of certain immune cells, including T-helper cells. This binding prevents the CD4 protein from interacting with other immune cells, thereby inhibiting the immune response. This activity is particularly beneficial in diseases where the immune system is overactive, such as autoimmune disorders and inflammatory conditions. Title: Applications of Zanolimumab Biosimilar Zanolimumab Biosimilar has shown promising results in preclinical studies for various diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis. In rheumatoid arthritis, the antibody has been shown to reduce inflammation and joint damage by inhibiting the activity of T-helper cells. In psoriasis, Zanolimumab Biosimilar has been found to improve skin lesions and reduce the severity of symptoms by targeting the immune cells responsible for the disease. In multiple sclerosis, the antibody has been shown to delay disease progression by modulating the immune response. Advantages of Zanolimumab Biosimilar Zanolimumab Biosimilar offers several advantages over the original antibody, including lower production costs, increased accessibility, and improved safety profile. As a biosimilar, it is produced using the same manufacturing process as the original antibody, but at a lower cost, making it more affordable for patients. This also allows for increased accessibility to treatment for patients in need. Furthermore, the humanized structure of Zanolimumab Biosimilar reduces the risk of immune reactions, making it a safer option for patients. Conclusion In conclusion, Zanolimumab Biosimilar is a promising therapeutic option for various diseases that target the CD4 protein. Its unique structure and activity make it an effective treatment for conditions where the immune system is overactive. With its lower production costs and improved safety profile, Zanolimumab Biosimilar has the potential to provide accessible and affordable treatment for patients in need. Further clinical trials and studies are needed to fully evaluate the efficacy and safety of this biosimilar, but it holds great promise in the field of immunotherapy.

Zarutatug Biosimilar – Research Grade, ProteoGenix, PX-TA2525-100

Zelminemab Biosimilar – Anti-ADCYAP1R1 mAb – Research Grade, ProteoGenix, PX-TA1612

Description of Zelminemab Biosimilar - Anti-ADCYAP1R1 mAb - Research Grade Zelminemab Biosimilar – Anti-ADCYAP1R1 mAb – Research Grade Zelminemab Biosimilar – Anti-ADCYAP1R1 mAb – Research Grade Introduction Zelminemab Biosimilar is a monoclonal antibody (mAb) that targets the Adenylate Cyclase Activating Polypeptide Receptor 1 (ADCYAP1R1). It is a research grade antibody that has shown promising results in pre-clinical studies for potential therapeutic applications. In this article, we will discuss the structure, activity, and potential applications of Zelminemab Biosimilar. Structure of Zelminemab Biosimilar Zelminemab Biosimilar is a recombinant humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region of the antibody is responsible for binding to its target, ADCYAP1R1. The constant region determines the effector functions of the antibody, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Activity of Zelminemab Biosimilar Zelminemab Biosimilar specifically binds to the extracellular domain of ADCYAP1R1, a G-protein coupled receptor that is highly expressed in various types of cancer, including breast, lung, and prostate cancer. By binding to ADCYAP1R1, Zelminemab Biosimilar inhibits the signaling pathway that promotes cancer cell growth and survival. This leads to reduced proliferation and increased cell death in cancer cells, making Zelminemab Biosimilar a potential anti- cancer therapeutic agent. Potential Applications of Zelminemab Biosimilar As mentioned earlier, Zelminemab Biosimilar has shown promising results in pre-clinical studies for potential therapeutic applications. Some of the potential applications of Zelminemab Biosimilar are: Cancer Treatment: Zelminemab Biosimilar has shown potential as an anti-cancer therapeutic agent by targeting ADCYAP1R1, which is overexpressed in various types of cancer. It has the potential to be used as a monotherapy or in combination with other anti-cancer treatments. Autoimmune Diseases: ADCYAP1R1 has also been implicated in the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Zelminemab Biosimilar has the potential to be used in the treatment of these diseases by inhibiting the signaling pathway mediated by ADCYAP1R1. Neurological Disorders: ADCYAP1R1 is also involved in the regulation of stress response and anxiety. Zelminemab Biosimilar has shown potential in pre-clinical studies for the treatment of anxiety disorders and other neurological disorders. Conclusion Zelminemab Biosimilar is a promising research grade antibody that specifically targets ADCYAP1R1, a receptor that is highly expressed in various diseases. Its unique mechanism of action makes it a potential therapeutic agent for the treatment of cancer, autoimmune diseases, and neurological disorders. Further clinical trials are needed to fully evaluate the efficacy and safety of Zelminemab Biosimilar, but its potential as a therapeutic antibody is promising.

Zemlikafusp alfa Biosimilar – Research Grade, ProteoGenix, PX-TA2526-100

Zenocutuzumab Biosimilar – Anti-ERBB2, ERBB3 mAb – Research Grade, ProteoGenix, PX-TA1493

Description of Zenocutuzumab Biosimilar - Anti-ERBB2, ERBB3 mAb - Research Grade Introduction Zenocutuzumab Biosimilar, also known as Anti-ERBB2, ERBB3 mAb, is a monoclonal antibody that has been developed as a potential therapeutic agent for the treatment of various cancers. This biosimilar is a highly specific and potent inhibitor of the ERBB2 and ERBB3 receptors, which are known to play a crucial role in the growth and survival of cancer cells. In this article, we will discuss the structure, activity, and potential applications of Zenocutuzumab Biosimilar in the field of cancer research. Structure of Zenocutuzumab Biosimilar Zenocutuzumab Biosimilar is a recombinant humanized monoclonal antibody that has been designed to target and block the activity of the ERBB2 and ERBB3 receptors. It is a biosimilar of the original Zenocutuzumab, which is a fully humanized monoclonal antibody. The biosimilar version has been developed using advanced biotechnological techniques, which ensure high levels of purity and consistency in its structure. The antibody is composed of two heavy chains and two light chains, which are linked by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL and CL1) and one variable domain (VL). The variable domains are responsible for binding to the specific target receptors, while the constant domains provide stability and effector functions. Mechanism of Action Zenocutuzumab Biosimilar exerts its anti- cancer activity by specifically binding to the extracellular domains of the ERBB2 and ERBB3 receptors, which are overexpressed in various types of cancer cells. This binding prevents the activation of downstream signaling pathways, which are responsible for promoting cell growth and survival. Additionally, the antibody also triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of cancer cells. Therapeutic Target: ERBB2 and ERBB3 Receptors The ERBB2 and ERBB3 receptors, also known as HER2 and HER3, respectively, belong to the epidermal growth factor receptor (EGFR) family. These receptors are often overexpressed in various types of cancer cells, including breast, lung, and gastric cancers. Overexpression of these receptors is associated with aggressive tumor growth, resistance to chemotherapy, and poor prognosis. Zenocutuzumab Biosimilar specifically targets these receptors, inhibiting their activity and preventing the growth and survival of cancer cells. This makes it a promising therapeutic agent for the treatment of HER2-positive and HER3-positive cancers. Potential Applications Zenocutuzumab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. It has the potential to be used as a monotherapy or in combination with other anti- cancer agents. Some of the potential applications of Zenocutuzumab Biosimilar include: – Treatment of HER2-positive breast cancer: Zenocutuzumab Biosimilar has shown promising results in HER2-positive breast cancer, both as a single agent and in combination with other anti- cancer drugs. – Treatment of HER3-positive lung cancer: Zenocutuzumab Biosimilar has shown efficacy in preclinical studies against HER3-positive lung cancer, which is often resistant to traditional chemotherapy. – Treatment of HER2-positive gastric cancer: Zenocutuzumab Biosimilar has shown promising results in preclinical studies against HER2-positive gastric cancer, which is a highly aggressive and difficult-to-treat cancer. Conclusion In conclusion, Zenocutuzumab Biosimilar is a highly specific and potent monoclonal antibody that targets the ERBB2 and ERBB3 receptors, which are overexpressed in various types of cancer cells. Its unique mechanism

Zilovertamab Biosimilar – Anti-ROR1 mAb – Research Grade, ProteoGenix, PX-TA1743

Description of Zilovertamab Biosimilar - Anti-ROR1 mAb - Research Grade Zilovertamab Biosimilar: A Promising Anti-ROR1 Monoclonal Antibody for Cancer Treatment Zilovertamab Biosimilar, also known as Anti-ROR1 mAb, is a monoclonal antibody that specifically targets the receptor tyrosine kinase-like orphan receptor 1 (ROR1). This biosimilar is a promising therapeutic agent for the treatment of various cancers, including solid tumors and hematologic malignancies. In this article, we will explore the structure, activity, and potential applications of Zilovertamab Biosimilar in cancer research. Structure of Zilovertamab Biosimilar Zilovertamab Biosimilar is a recombinant humanized monoclonal antibody that is derived from the parent antibody, cirmtuzumab. It is composed of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa. The antibody has a unique structure that allows it to specifically bind to ROR1, a cell surface receptor that is overexpressed in many cancer cells. The binding site of Zilovertamab Biosimilar is located in the variable region of the antibody, which is responsible for recognizing and binding to its target. This region is highly specific and allows for the antibody to selectively bind to ROR1, without affecting other receptors or proteins in the body. Activity of Zilovertamab Biosimilar The main mechanism of action of Zilovertamab Biosimilar is through its binding to ROR1 on the surface of cancer cells. This binding leads to the inhibition of ROR1 signaling pathways, which are involved in promoting cancer cell growth, survival, and metastasis. By blocking these pathways, Zilovertamab Biosimilar can effectively inhibit the growth and spread of cancer cells. Moreover, Zilovertamab Biosimilar also has an immunomodulatory activity, as it can bind to ROR1-expressing immune cells and activate them to attack cancer cells. This dual mechanism of action makes Zilovertamab Biosimilar a potent therapeutic agent for cancer treatment. Applications of Zilovertamab Biosimilar The potential applications of Zilovertamab Biosimilar are vast, as it can be used in various types of cancer. Its high specificity and activity against ROR1 make it a promising candidate for targeted therapy in solid tumors, such as breast, lung, and ovarian cancer. It can also be used in hematologic malignancies, including leukemia and lymphoma, as ROR1 is highly expressed in these types of cancer cells. Zilovertamab Biosimilar can be used as a monotherapy or in combination with other anti- cancer agents, such as chemotherapy, radiotherapy, or other targeted therapies. Its immunomodulatory activity also makes it a potential candidate for combination therapy with immune checkpoint inhibitors, enhancing the anti-tumor immune response. Conclusion Zilovertamab Biosimilar, also known as Anti-ROR1 mAb, is a promising monoclonal antibody for cancer treatment. Its unique structure, high specificity, and dual mechanism of action make it a potent therapeutic agent for various types of cancer. Further clinical trials and research are needed to fully explore the potential of Zilovertamab Biosimilar in cancer treatment and improve patient outcomes. Keywords: antibody, therapeutic target, Zilovertamab Biosimilar, Anti-ROR1 mAb, monoclonal antibody, cancer treatment, ROR1, structure, activity, applications.

Ziltivekimab Biosimilar – Anti-IL6 mAb – Research Grade, ProteoGenix, PX-TA1613

Description of Ziltivekimab Biosimilar - Anti-IL6 mAb - Research Grade Introduction Ziltivekimab Biosimilar is a novel anti-IL6 monoclonal antibody (mAb) that has been developed for therapeutic use. It is a research grade antibody that is designed to target and block the activity of interleukin-6 (IL-6), a pro-inflammatory cytokine that plays a critical role in various diseases. Structure of Ziltivekimab Biosimilar Ziltivekimab Biosimilar is a fully humanized IgG1 monoclonal antibody that is produced using recombinant DNA technology. It is composed of two heavy chains and two light chains, each consisting of variable and constant regions. The variable regions are responsible for binding to IL-6, while the constant regions are important for effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Mechanism of Action Ziltivekimab Biosimilar works by binding to IL-6 and preventing it from interacting with its receptors. IL-6 is a key mediator of inflammation and is involved in various physiological processes, including immune response, hematopoiesis, and tissue regeneration. However, excessive or dysregulated production of IL-6 has been linked to the pathogenesis of several diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. By blocking IL-6 activity, Ziltivekimab Biosimilar helps to reduce inflammation and improve disease symptoms. Applications of Ziltivekimab Biosimilar Ziltivekimab Biosimilar has potential therapeutic applications in various inflammatory and autoimmune diseases. It has been studied in preclinical and clinical trials for the treatment of rheumatoid arthritis, systemic lupus erythematosus, and cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy. In addition, Ziltivekimab Biosimilar has shown promising results in a phase II clinical trial for the treatment of COVID-19 patients with severe respiratory distress. Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects the joints, causing pain, stiffness, and swelling. IL-6 is a key mediator of joint inflammation in RA, and its levels are elevated in the synovial fluid and serum of RA patients. Ziltivekimab Biosimilar has been shown to effectively reduce disease activity and improve symptoms in RA patients, making it a potential treatment option for this disease. Systemic Lupus Erythematosus Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can affect multiple organs and tissues. IL-6 has been implicated in the pathogenesis of SLE, and its levels are elevated in SLE patients. Ziltivekimab Biosimilar has shown promising results in reducing disease activity and improving symptoms in SLE patients, making it a potential treatment option for this disease. Cytokine Release Syndrome Cytokine release syndrome (CRS) is a potentially life-threatening complication that can occur in patients receiving CAR T-cell therapy. It is characterized by a rapid and excessive release of cytokines, including IL-6, which can lead to systemic inflammation and organ damage. Ziltivekimab Biosimilar has been shown to effectively block IL-6 and reduce CRS symptoms in preclinical studies, making it a potential treatment option for this complication. COVID-19 COVID-19 is a viral respiratory illness caused by the SARS-CoV-2 virus. IL-6 has been identified as a major driver of the cytokine storm that occurs in severe cases of COVID-19, leading to respiratory failure and death. Ziltivekimab Biosimilar has shown promising results in reducing IL-6 levels and improving respiratory function in COVID-19 patients, making it a potential treatment option for this disease. Conclusion In conclusion, Ziltivekimab Biosimilar is

Zolbetuximab Biosimilar – Anti-CLDN18.2 mAb – Research Grade, ProteoGenix, PX-TA1013

Description of Zolbetuximab Biosimilar - Anti-CLDN18.2 mAb - Research Grade General information about Zolbetuximab Zolbetiximab is a monoclonal antibody currently under investigation as a potential treatment for pancreatic tumors and gastrointestinal adenocarcinomas. This therapeutic antibody targets isoform 2 of Claudin-18. Claudin-18 protein is encoded by CLDN18 gene and is a member of claudin family of proteins. The members of this family of proteins are key components in the structure of tight junctions also known as zonulae occludentes. Tight junctions form the paracellular space which is the intercellular space between epithelial cells. Claudin family of proteins contain four transmembrane domain whose C-terminus and N-terminus are both located in the cytoplasm. The isoform 2 of CLDN18 protein is restricted to differentiated epithelial cells located at the gastric mucosa tight junctions. However, once malignant transformation occurs, the cell polarity is disturbed and results in isoform 2 CLD18 epitopes being exposed on the surface of cancer cells. Hence, isoform 2 of CLDN18 has been considered as a potential candidate for in targeted therapy for different forms of cancer such as esophagus, pancreatic, ovarian and lung tumors. Zolbetiximab binds to isoform 2 CLDN18 which results in immune-mediated lysis of this protein. The attachment of Zolbetiximab to isoform 2 CLDN18 causes cancer cell death as a result. Zolbetiximab was in phase II clinical trials as of January 2013. Preliminary results based on phase II ‘FAST’ trial supported zolbetiximab as a potential drug for advanced gastric cancer. Currently zolbetiximab is in phase III of clinical trials. So far zolbetuximab therapy has been well tolerated, Furthermore, the monoclonal antibody showed antitumor activity among patient with isoform 2 CLDN18-positive advanced gastric or gastroesophageal junction cancers. The phase III study consists of administering Zolbetiximab plus mFOLFOX6 vs placebo plus mFOLFOX6. mFOLFOX6 is a combination of three different chemotherapies such as Oxaliplatin, Leucovorin, and Fluorouracil which are also a current treatment option for patients with advanced gastric or gastroesophageal junction adenocarcinoma or cancer. This product is for research use only.